Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
495
Recruiting Now
495
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT06351514 Phase 3
Recruiting
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Thet...
Condition
Schizophrenia; Negative Type
Enrollment
40 pts
Location
Singapore
Sponsor
Institute of Mental Health, Si
NCT04087421 Phase 3
Recruiting
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Lo...
Condition
Low Anterior Resection Syndrome
Enrollment
114 pts
Location
Denmark
Sponsor
University of Aarhus
NCT06860984 Phase 3
Recruiting
Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endos...
Condition
Biliary Disease
Enrollment
44 pts
Location
Egypt
Sponsor
Tanta University
NCT06911112 Phase 3
Recruiting
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as a...
Condition
Major Depressive Disorder
Enrollment
200 pts
Location
United States
Sponsor
Neurocrine Biosciences
NCT06893016 Phase 3
Recruiting
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Condition
Obesity
Enrollment
640 pts
Location
China
Sponsor
Guangdong Raynovent Biotech Co
NCT06903884 Phase 3
Recruiting
3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratocon...
Condition
Vernal Keratoconjunctivitis
Enrollment
94 pts
Location
Hong Kong
Sponsor
The University of Hong Kong
NCT07112144 Phase 3
Recruiting
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With V...
Condition
Prevent Whooping Cough
Enrollment
1,650 pts
Location
China
Sponsor
Changchun BCHT Biotechnology C
NCT06951698 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic ...
Condition
Bipolar-I Disorder With Mania or Mania With Mixed Features
Enrollment
274 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT07039916 Phase 3
Recruiting
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild t...
Condition
Generalized Myasthenia Gravis
Enrollment
231 pts
Location
United States, Argentina, Czechia
Sponsor
Immunovant Sciences GmbH
NCT07071519 Phase 3
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ul...
Condition
Ulcerative Colitis
Enrollment
120 pts
Location
United States, Belgium, Brazil
Sponsor
AbbVie
NCT06417775 Phase 3
Recruiting
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity...
Condition
Migraine
Enrollment
496 pts
Location
United States, Puerto Rico
Sponsor
AbbVie
NCT06394284 Phase 3
Recruiting
Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Rel...
Condition
PTSD, Post Traumatic Stress Disorder
Enrollment
60 pts
Location
Israel
Sponsor
Herzog Hospital
NCT06395441 Phase 3
Recruiting
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
Condition
Malignant Solid Neoplasm
Enrollment
160 pts
Location
United States
Sponsor
Mayo Clinic
NCT05799378 Phase 3
Recruiting
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Condition
Systemic Lupus Erythematosus
Enrollment
330 pts
Location
United States
Sponsor
NYU Langone Health
NCT07135167 Phase 3
Recruiting
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using ...
Condition
Down Syndrome (DS)
Enrollment
225 pts
Location
United States
Sponsor
Woolfson Eye Institute
NCT05092984 Phase 3
Recruiting
Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)
Condition
Rheumatoid Arthritis
Enrollment
154 pts
Location
France
Sponsor
University Hospital, Strasbour
NCT03394365 Phase 3
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associ...
Condition
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Enrollment
115 pts
Location
United States, Australia, Austria
Sponsor
Pierre Fabre Medicament
NCT05751967 Phase 3
Recruiting
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary ...
Condition
Primary Biliary Cholangitis
Enrollment
150 pts
Location
China
Sponsor
Xijing Hospital of Digestive D
NCT06958211 Phase 3
Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W...
Condition
Hidradenitis Suppurativa
Enrollment
550 pts
Location
United States, Belgium, Bulgaria
Sponsor
Incyte Corporation
NCT05813964 Phase 3
Recruiting
Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM...
Condition
HIV/AIDS
Enrollment
524 pts
Location
France, Thailand
Sponsor
ANRS, Emerging Infectious Dise
NCT06352632 Phase 3
Recruiting
ACT-GLOBAL Adaptive Platform Trial for Stroke
Condition
Stroke
Enrollment
20,000 pts
Location
Australia, Canada
Sponsor
The George Institute
NCT06635798 Phase 3
Recruiting
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics an...
Condition
Tetanus
Enrollment
582 pts
Location
China
Sponsor
Genrix (Shanghai) Biopharmaceu
NCT07187206 Phase 3
Recruiting
Safety and Efficacy of FETO in CDH Phase III
Condition
Congenital Diaphragmatic Hernia
Enrollment
75 pts
Location
United States
Sponsor
Children's Hospital Medical Ce
NCT06387147 Phase 3
Recruiting
ORal Antibiotics in Acute Mesenteric Ischemia
Condition
Acute Mesenteric Ischemia
Enrollment
196 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT06994507 Phase 3
Recruiting
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Ne...
Condition
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Enrollment
352 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology